Open AccessA phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer
Author(s) -
Paula Demétrio De Souza França,
Susanne Kossatz,
Christian Brand,
Daniella Karassawa Zai,
Sheryl Roberts,
Navjot Guru,
Dauren Adilbay,
Audrey Mauguen,
Cristina Valero,
Wolfgang Weber,
Heiko Schöder,
Ronald Ghossein,
Ian Ganly,
Snehal G. Patel,
Thomas Reiner
Publication year - 2021
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-021-05372-6
Subject(s) - medicine , ex vivo , cancer , in vivo , pathology , biopsy , nuclear medicine , biology , microbiology and biotechnology
Visual inspection and biopsy is the current standard of care for oral cancer diagnosis, but is subject to misinterpretation and consequently to misdiagnosis. Topically applied PARPi-FL is a molecularly specific, fluorescent contrast-based approach that may fulfill the unmet need for a simple, in vivo, non-invasive, cost-effective, point-of-care method for the early diagnosis of oral cancer. Here, we present results from a phase I safety and feasibility study on fluorescent, topically applied PARPi-FL. Twelve patients with a histologically proven oral squamous cell carcinoma (OSCC) gargled a PARPi-FL solution for 60 s (15 mL, 100 nM, 250 nM, 500 nM, or 1000 nM), followed by gargling a clearing solution for 60 s. Fluorescence measurements of the lesion and surrounding oral mucosa were taken before PARPi-FL application, after PARPi-FL application, and after clearing. Blood pressure, oxygen levels, clinical chemistry, and CBC were obtained before and after tracer administration.